Targeted therapy shows promise for advanced breast cancer
LINCOLN, Neb. (KLKN) – An experimental treatment is showing promise for people with the most common form of advanced-stage breast cancer.
It showed that when people took the oral treatment Capivasertib combined with an endocrine therapy already used the time without disease progression doubled.
The trial involved 708 adults with hr-positive, her2-low or -negative breast cancer whose disease has recurred or progressed during or after certain previous treatments.
About three-quarters of women with metastatic breast cancer have h-r-positive breast cancer.
Experts say it is important to continue watching for the results of further trials to see whether the treatment impacts overall survival rates.